Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Josip Arlica, MD Altiora Training Program “Train to Gain”
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
A Blueprint For Clinical Research: Standard Operating Procedures
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
Good Clinical Practice in Research
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Monitoring and Auditing
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
Tool Summary Sheet Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites. Tool: Sponsor Responsibilities.
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Overview of Good Clinical Practices (GCPs)
Monitoring and Special Considerations for Multi-Center Trials
Quality Assurance in Bio-availability / Bio-equivalence studies. DR
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
ANJALI JADHAV ANKITA SINGH ANUJA AHIRE ANURADHA PRASAD BEVIN D’SOUZA.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Boehringer Ingelheim Investigator Meeting Study POLO- AML-2 February 23, 2013/Toronto Behbood Sadrolhefazi Therapeutic Area Specialist/ Oncology.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Investigational Devices and Humanitarian Use Devices June 2007.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
IP Accountability in Outpatient Clinical Trials
Sponsor Visits and Monitoring
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance.
ICH guidelines……….. INVESTIGATOR INVESTIGATOR Investigator's Qualifications and agreements The investigator(s) should be qualified by education, training,
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Good Clinical Practice (GCP) and Monitoring Practices
Responsibilities of Sponsor, Investigator and Monitor
Good Clinical Practice
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Quality Control SOP 3.12 Release Date: 08/10/2015.
Gilbert Ogetii KEMRI-Wellcome Trust Research Programme Kilifi, Kenya
Good Clinical Practice in Research
Good clinical practice
Presentation transcript:

Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin, CCRA

Clinical Trials Network Monitor’s Responsibilities – ICH E6 Section 5.18 Overall Purpose of Monitoring  Verify the rights and well-being of human subjects are protected  Verify that reported trial data are accurate, complete and verifiable from source documents  Verify the study is conducted in compliance with the study protocol, GCP guidelines and applicable regulations

Clinical Trials Network Selection and Qualifications of Monitors Should be appointed by the sponsor Should be appropriately trained, and should have the scientific and/or clinical knowledge needed to monitor the trial adequately Should be thoroughly familiar with the investigational product(s), the protocol, consent and any other written information

Clinical Trials Network Monitor Responsibilities Act as main line of communication between the sponsor and investigator Follow sponsor SOPs for monitoring and protocol specific requirements Site-selection / Pre-study visit  Study-Mandated Criteria Investigator qualifications Facilities and Equipment  Basic Investigator Criteria Reputation / Access to Subjects / Concurrent studies

Clinical Trials Network Study Initiation Visit Detailed explanation of protocol  CRF review  AEs  Schedule of Events Verify regulatory approvals in place Assess supply inventory  Confirm labeling / organization of investigational product

Clinical Trials Network Routine / Interim Monitoring visits Investigator compliance  With protocol, regulations and GCP guidelines Check accuracy and completeness of CRFs and source against one another  Data are reported accurately  Modifications to the IP are well documented  AEs and concomitant medications reviewed  Withdrawals and dropouts reported  Consent obtained

Clinical Trials Network Routine / Interim Monitoring visits Evaluate study conduct  Review for protocol deviations and reporting  Review recruitment  Check supplies Factory influencing the rate of visits  Type of disease  Level of complicated medical condition  Complexity of study design  Previous performance

Clinical Trials Network Study Closeout Visit Collect CRFs  Outstanding corrections are made Ship and/or pick up all remaining clinical supplies Confirms regulatory files are complete Review record retention policies Clarify remaining sponsor commitments

Clinical Trials Network Monitoring Report Written report to sponsor after each site visit or trial-related communication. Should include:  Date of visit  Site  Name of monitor  Name of investigator and personnel contacted  Summary of information reviewed  Significant findings and corrective action plans Review and follow up on corrective actions should be documented

Clinical Trials Network Audits Independent of the clinical trials/systems Independent of and separate from routine monitoring or QC functions To evaluate trial conduct and compliance with protocol, SOPs, GCP and applicable regulatory requirements

Clinical Trials Network Auditing Procedures Should be conducted in accordance with Sponsor SOPs Based on:  Type and complexity of trial  Level of risk to the subject  Regulatory reporting requirements  Identified problems Audit findings should be documented When required by law, sponsor should provide an audit certificate

Clinical Trials Network Noncompliance Prompt action by sponsor should be taken to secure compliance If serious and/or persistent noncompliance on the part of an investigator/institution, the sponsor may terminate participation in the trial  Sponsor should promptly notify regulatory authority(ies).